We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Collaboration to Focus on Women’s Health Diagnostic Solutions

By LabMedica International staff writers
Posted on 18 Jun 2013
Two companies have entered into a collaboration that will feature the national availability of a cervical cancer-screening test in addition to developing and expanding access to diagnostic solutions for women’s health.

Quest Diagnostics (Madison, N.J. More...
USA), a global diagnostic information services company, and Hologic, Inc. (Bedford, MA, USA), a developer, manufacturer, and supplier of diagnostics products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women, have entered into a strategic alliance to more broadly offer testing based on Hologic’s Aptima range of products, as well as to codevelop and promote advanced diagnostic solutions to improve women's health.

Under the nonexclusive agreement, which has an initial term of five years, the companies will focus primarily on clinical areas critical to the health of women. Quest Diagnostics will develop a broader offering of services based on Hologic’s Aptima family of products, which includes US Food and Drug Administration (FDA; Silver Spring, MD, USA)-approved or cleared assays for human papillomavirus (HPV), HPV genotyping, Chlamydia, gonorrhea, and Trichomonas vaginalis. In addition, Quest Diagnostics will continue to utilize Hologic's leading line of ThinPrep liquid-based cytology products.

Quest Diagnostics will also continue to offer Hologic’s Aptima HPV mRNA-based assay nationally. The Aptima HPV assay detects messenger RNA overexpressed from two viral oncogenes that are integral to the development of cervical cancer. Hologic’s Aptima HPV assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens.

The companies will also explore opportunities to develop and expand access to new diagnostic solutions for women’s health. In addition, they will implement joint programs to advance women’s health issues with medical associations and patient advocacy groups and to sponsor research. Financial terms of the collaboration were not disclosed.

“Our relationship with Hologic also demonstrates our progress executing on our restore growth and operational excellence strategies,” said Mr. Rusckowski, Quest’s CEO. “With this alliance, we will strengthen the specialization and competitiveness of our women's health business. We are also working more closely and strategically with suppliers, and this alliance is the first under our new, highly rigorous supplier engagement model, which we unveiled at our first ever Supplier Forum in March.”

Related Links:

Quest Diagnostics
Hologic
US Food and Drug Administration



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.